Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Momelotinib for the treatment of myelofibrosis

Prithviraj Bose

Blood (2024) 144 (7): 708–713.

https://doi.org/10.1182/blood.2023023719

Published: 2024

Journal Articles

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Holly Lee, Paola Neri, Nizar J. Bahlis

Blood (2024) 143 (13): 1211–1217.

https://doi.org/10.1182/blood.2023022499

Published: 2024

Includes: Supplemental data

Journal Articles

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Edward J. Benz, Jr., Leslie E. Silberstein, Julie Panepinto

Blood (2024) 143 (11): 967–970.

https://doi.org/10.1182/blood.2023021598

Published: 2024

Journal Articles

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease

Dina S. Parekh, William A. Eaton, Swee Lay Thein

Blood (2024) 143 (10): 866–871.

https://doi.org/10.1182/blood.2023021167

Published: 2024

Journal Articles

CAR T-cell therapy in multiple myeloma: mission accomplished?

Leo Rasche, Michael Hudecek, Hermann Einsele

Blood (2024) 143 (4): 305–310.

https://doi.org/10.1182/blood.2023021221

Published: 2024

Journal Articles

Macrophage heterogeneity in the single-cell era: facts and artifacts

David A. Hume, Susan M. Millard, Allison R. Pettit

Blood (2023) 142 (16): 1339–1347.

https://doi.org/10.1182/blood.2023020597

Published: 2023

Journal Articles

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Philip A. Thompson, Constantine S. Tam

Blood (2023) 141 (26): 3137–3142.

https://doi.org/10.1182/blood.2023020240

Published: 2023

Includes: Supplemental data

Journal Articles

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Antonino Carbone, Annunziata Gloghini, Carmelo Carlo-Stella

Blood (2023) 141 (18): 2187–2193.

https://doi.org/10.1182/blood.2022016590

Published: 2023

Journal Articles

Vaccine-induced immune thrombotic thrombocytopenia

Douglas B. Cines, Andreas Greinacher

Blood (2023) 141 (14): 1659–1665.

https://doi.org/10.1182/blood.2022017696

Published: 2023

Journal Articles

Minimal information for reporting a genomics experiment

Kostiantyn Dreval, Paul C. Boutros, Ryan D. Morin

Blood (2022) 140 (24): 2549–2555.

https://doi.org/10.1182/blood.2022016095

Published: 2022

Includes: Supplemental data

Journal Articles

MRD in multiple myeloma: does CR really matter?

Bruno Paiva, Jesus San-Miguel, Hervé Avet-Loiseau

Blood (2022) 140 (23): 2423–2428.

https://doi.org/10.1182/blood.2022016170

Published: 2022

Journal Articles

Daratumumab in AL amyloidosis

Ashutosh D. Wechalekar, Vaishali Sanchorawala

Blood (2022) 140 (22): 2317–2322.

https://doi.org/10.1182/blood.2021014613

Published: 2022

Journal Articles

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Florence Vallelian, Paul W. Buehler, Dominik J. Schaer

Blood (2022) 140 (17): 1837–1844.

https://doi.org/10.1182/blood.2022015596

Published: 2022

Journal Articles

Avapritinib for advanced systemic mastocytosis

Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo

Blood (2022) 140 (15): 1667–1673.

https://doi.org/10.1182/blood.2021014612

Published: 2022

Journal Articles

Inflammation and myeloid malignancy: quenching the flame

Ryan J. Stubbins, Uwe Platzbecker, Aly Karsan

Blood (2022) 140 (10): 1067–1074.

https://doi.org/10.1182/blood.2021015162

Published: 2022

Journal Articles

Anticoagulation in hospitalized patients with COVID-19

Lisa Baumann Kreuziger, Michelle Sholzberg, Mary Cushman

Blood (2022) 140 (8): 809–814.

https://doi.org/10.1182/blood.2021014527

Published: 2022

Journal Articles

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Eleonora Calabretta, Mehdi Hamadani, Pier Luigi Zinzani, Paolo Caimi, Carmelo Carlo-Stella

Blood (2022) 140 (4): 303–308.

https://doi.org/10.1182/blood.2021014663

Published: 2022

Journal Articles

Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

Noelle V. Frey

Blood (2022) 140 (1): 11–15.

https://doi.org/10.1182/blood.2021014892

Published: 2022

Journal Articles

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?

Philippe Moreau, Cyrille Touzeau

Blood (2022) 139 (26): 3681–3687.

https://doi.org/10.1182/blood.2021014611

Published: 2022

Journal Articles

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

David T. Yeung, Naranie Shanmuganathan, Timothy P. Hughes

Blood (2022) 139 (24): 3474–3479.

https://doi.org/10.1182/blood.2021014689

Published: 2022

NARROW

Momelotinib for the treatment of myelofibrosis

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia

Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease

CAR T-cell therapy in multiple myeloma: mission accomplished?

Macrophage heterogeneity in the single-cell era: facts and artifacts

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

Vaccine-induced immune thrombotic thrombocytopenia

Minimal information for reporting a genomics experiment

MRD in multiple myeloma: does CR really matter?

Daratumumab in AL amyloidosis

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics

Avapritinib for advanced systemic mastocytosis

Inflammation and myeloid malignancy: quenching the flame

Anticoagulation in hospitalized patients with COVID-19

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia

T-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only